## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.6% below STRENGTH zone (3.0-6.0%); PEG 1.44 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($465.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: United Therapeutics Investor Relations | 20260105T120859 | Neutral | Relevance: 100%
- United Therapeutics Corporation announced that its Chairperson and Chief Executive Officer, Dr. Martine Rothblatt, will present a company overview and update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be accessible via a live webcast on the company's investor relations website, with an archived version available for 30 days afterward. The company will discuss its mission to innovate for unmet medical needs and its public benefit corporation status.

**2. Allspring Global Investments Holdings LLC Acquires 4,944 Shares of United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20260103T080920 | Somewhat-Bullish | Relevance: 100%
- Allspring Global Investments Holdings LLC has increased its stake in United Therapeutics (NASDAQ: UTHR) by 5.8%, now owning 89,809 shares valued at $39.35 million. While institutional ownership is high at 94.08% and analysts rate the stock a "Moderate Buy" with an average target of $505, there has been significant insider selling, totaling $287.9 million in the last 90 days. The biotechnology company recently beat EPS expectations but slightly missed revenue estimates, maintaining a strong net margin of 40.65%.

**3. United Therapeutics Corporation $UTHR Shares Bought by Merit Financial Group LLC**
- Source: MarketBeat | 20260103T110920 | Somewhat-Bullish | Relevance: 100%
- Merit Financial Group LLC has significantly increased its stake in United Therapeutics Corporation (UTHR), boosting its holdings by 56.3% in the third quarter to 7,416 shares valued at approximately $3.11 million. This comes as United Therapeutics reported strong Q3 earnings, beating EPS estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $505. However, the company has also seen substantial insider selling recently, with insiders disposing of over 618,000 shares worth around $288 million in the past 90 days.

**4. How United Therapeutics Corporation (UTHR) Affects Rotational Strategy Timing**
- Source: Stock Traders Daily | 20260103T174000 | Neutral | Relevance: 96%
- This article analyzes United Therapeutics Corporation (UTHR) for rotational strategy timing, highlighting weak near-term sentiment despite potential long-term strength. It details specific institutional trading strategies, including long, breakout, and short positions, based on AI-generated signals and multi-timeframe analysis. The analysis provides key support and resistance levels across different time horizons for UTHR.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($17.98M) |
| Sells | 61 ($30.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $31M sold (61 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.1x stretched relative to 6% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.1B |
| Beta | 0.84 |
| 52W Range | $266.98 - $519.99 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.1 |
| Current P/E | 18.1 |
| YoY Growth | 5.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 5.6pp (needs >3.0% for momentum thesis). Underperforming sector by 3.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-3.52), momentum weakening. RSI neutral at 49. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.63% (CS: 11) | Weak |
| RSI_14 | 48.7 | Neutral |
| MACD Histogram | -3.52 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 1.030x | Above |
| vs SMA200 | 1.335x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $489.69
- **Stop Loss:** $465.03 (5.0% risk)
- **Target:** $514.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 34
- **Position Value:** $16,649.46
- **Portfolio %:** 16.65%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*